PCMC
ONCY

Planning Capital Management Corporation’s Oncolytics Biotech ONCY Stock Holding History

Planning Capital Management Corporation’s Portfolio ONCY Stock Details ONCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-215
Closed -$291 – 687
2023
Q4 		$291 Buy
+215
New +$336 ﹤0.01% 636

Other funds holding ONCY

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
CIBC World Market
CIBC World Market Toronto, Ontario, Canada $61.3B AUM 39.33% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Planning Capital Management Corporation's ONCY Position: Q1 2024 in Review

Planning Capital Management Corporation sold out of Oncolytics Biotech (ONCY) in Q1 2024, closing a stake of 215 shares — an estimated $291 sold.

Planning Capital Management Corporation first reported a position in ONCY in Q4 2023 and held it in 1 quarter. The position peaked at $291 in Q4 2023. 36 funds tracked by Wall St. Rank hold ONCY as of Q1 2024.

  • Planning Capital Management Corporation reported no remaining Oncolytics Biotech position as of Q1 2024 after selling out during the quarter.
  • Planning Capital Management Corporation sold 215 Oncolytics Biotech shares in Q1 2024, an estimated $291.
  • Planning Capital Management Corporation first reported a position in Oncolytics Biotech in Q4 2023 and held it in 1 quarter.
  • Planning Capital Management Corporation's Oncolytics Biotech position peaked at $291 in Q4 2023.
  • 36 funds tracked by Wall St. Rank held Oncolytics Biotech as of Q1 2024.

Based on Planning Capital Management Corporation's 13F filing for Q1 2024, filed 26 Apr 2024.